| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
2,6-Sialylation of Cell-Surface N-Glycans Inhibits Glioma Formation in Vivo1
Chicago Institute for Neurosurgery and Neuroresearch, Chicago, Illinois 60614
Human gliomas express very high levels of cell-surface
2,3-linked terminal sialic acids on glycoproteins bearing N-linked oligosaccharides, most notably on
3ß1 integrin, which is the predominant integrin found in these tumors.
2,6-linked terminal sialic acids, however, are not expressed. Two stable transfectants were made using a tumorigenic human glioma cell line, U-373 MG. Galß1,4GlcNAc
2,6-sialyltransferase (ST6Gal I) transfectants were made to replace the endogenous
2,3-linked sialic acids with
2,6-linked sialic acids. And Galß1,3(4)GlcNAc
2,3-sialyltransferase (ST3Gal III) transfectants were made to increase further the expression of cell-surface, N-glycan,
2,3-linked sialic acids. Although ST3Gal III transfection resulted in increased invasivity when compared with parental U-373 MG and vector-transfected control cells in vitro, ST6Gal I transfection abolished invasion in vitro and induced alterations in both cell morphology, cell-spreading, and adhesion-mediated protein tyrosine phosphorylation. Furthermore, the ST6Gal I transfectants produced no intracranial tumors in severe combined immunodeficient mice, whereas parental U-373 MG cells, the vector-transfected control cells, and ST3Gal III-transfected U-373 MG cells did. These results suggest that both the linkage and expression levels of the terminal sialic acids of
3ß1 integrin N-glycans play an important role in glioma cell-extracellular matrix interactions. Thus, manipulating ST6Gal I gene expression may have therapeutic potential for the treatment of malignant gliomas.
This article has been cited by other articles:
![]() |
J. Du, M A. Meledeo, Z. Wang, H. S Khanna, V. D P Paruchuri, and K. J Yarema Metabolic glycoengineering: Sialic acid and beyond Glycobiology, December 1, 2009; 19(12): 1382 - 1401. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lee, H.-J. Lee, S. Bae, and Y.-S. Lee Protein Sialylation by Sialyltransferase Involves Radiation Resistance Mol. Cancer Res., August 1, 2008; 6(8): 1316 - 1325. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Li, K. Ishihara, T. Yokota, T. Nakagawa, N. Koyama, J. Jin, Y. Mizuno-Horikawa, X. Wang, E. Miyoshi, N. Taniguchi, et al. Reduced {alpha}4 1 Integrin/VCAM-1 Interactions Lead to Impaired Pre-B Cell Repopulation in Alpha 1,6-Fucosyltransferase Deficient Mice Glycobiology, January 1, 2008; 18(1): 114 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhao, S. Itoh, X. Wang, T. Isaji, E. Miyoshi, Y. Kariya, K. Miyazaki, N. Kawasaki, N. Taniguchi, and J. Gu Deletion of Core Fucosylation on {alpha}3beta1 Integrin Down-regulates Its Functions J. Biol. Chem., December 15, 2006; 281(50): 38343 - 38350. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhao, T. Nakagawa, S. Itoh, K.-i. Inamori, T. Isaji, Y. Kariya, A. Kondo, E. Miyoshi, K. Miyazaki, N. Kawasaki, et al. N-Acetylglucosaminyltransferase III Antagonizes the Effect of N-Acetylglucosaminyltransferase V on {alpha}3beta1 Integrin-mediated Cell Migration J. Biol. Chem., October 27, 2006; 281(43): 32122 - 32130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chiricolo, N. Malagolini, S. Bonfiglioli, and F. Dall'Olio Phenotypic changes induced by expression of {beta}-galactoside {alpha}2,6 sialyltransferase I in the human colon cancer cell line SW948 Glycobiology, February 1, 2006; 16(2): 146 - 154. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |